Serum Magnesium, Prescribed Magnesium Replacement and Cardiovascular Events in Adults with Type 2 Diabetes: A National Cohort Study in U.S. Veterans
Yin Y, Cheng Y, Zullo AR, Shao Y, Sheriff HM, Faselis C, Liu S, Ahmed A, Zeng-Treitler Q, Wu WC
Nutrients · 3 citas
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Office of Research and Development, Health Services Research and Development
- Gobierno
- the Washington DC VA Medical Center
- Gobierno
- National Health Lung and Blood Institute of the NIH Office
- Gobierno
- National Health Lung and Blood Institute of the NIH
Según 4 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2025-06-21 · Nutrients · vol. 17 · número 13 · pág. 2067
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 3 citas · más que el 81% de estudios similares · 1.5× el promedio de su campo
- Referencias
- 52 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Potassium and Related Disorders
- Palabras clave
- Magnesium, Type 2 diabetes, Medicine, Cohort, Diabetes mellitus, Cohort study, Internal medicine, Endocrinology, Chemistry
- MeSH
- humans, cardiovascular diseases, diabetes mellitus, type 2, magnesium deficiency, magnesium, retrospective studies, cohort studies, aged, middle aged, veterans, united states, female, male
10 autores
- Ying Yin🇺🇸George Washington University; Veterans Health Administration
- Yan Cheng🇺🇸George Washington University; Veterans Health Administration
- Andrew R. Zullo🇺🇸Providence College; Brown University; Veterans Health Administration
- Yijun Shao🇺🇸George Washington University; Veterans Health Administration
- Helen M. Sheriff🇺🇸George Washington University; Veterans Health Administration
- Charles J. Faselis🇺🇸Uniformed Services University of the Health Sciences; George Washington University; Veterans Health Administration
- Simin Liu🇺🇸University of California, Irvine
- Ali Ahmed🇺🇸Georgetown University; George Washington University; Veterans Health Administration
- Qing Zeng‐Treitler🇺🇸George Washington University; Veterans Health Administration
- Wen‐Chih Wu🇺🇸 · autor de correspondenciaProvidence College; Brown University; Veterans Health Administration
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
To investigate the relationship between serum magnesium levels, prescribed oral magnesium replacement, and major adverse cardiovascular events (MACE) in type-2 diabetes mellitus (T2D).
Research design and methods
This nationwide retrospective study analyzed 1,284,940 US Veterans (≥18 years) with T2D who had outpatient serum magnesium testing between 1999-2021 in the Veterans Health Administration. The relationship between serum magnesium levels and MACE (hospitalizations for acute myocardial infarction, heart failure, ischemic stroke, or all-cause mortality) was determined using multivariable-adjusted Cox-regression models. Using a new-user-design and propensity-score-matching approach, we further related the use of prescribed oral magnesium and MACE among patients with hypomagnesemia (serum magnesium <1.8 mg/dL) and normomagnesemia (serum magnesium 1.8-2.3 mg/dL).
Results
Of 1,284,940 patients with T2D, 229,210 (17.8%) patients had hypomagnesemia, and 117,674 (9.2%) patients had hypermagnesemia (serum magnesium >2.3 mg/dL). Compared to patients with normomagnesemia (serum magnesium 1.8-2.3 mg/dL), those with either hypomagnesemia or hypermagnesemia had elevated hazards for MACE. The risk increased with the severity of serum magnesium abnormalities in both directions-low (hazard ratios [HRs] 1.11-1.20) and high (HRs 1.04-1.39)-in a parabolic pattern. Oral magnesium was prescribed to 9.7% and 0.7% of patients with hypomagnesemia and normomagnesemia, respectively. After propensity-score-matching balanced across 64 baseline characteristics, oral magnesium was associated with a lower MACE risk in 40,766 matched patients with hypomagnesemia (HR 0.89; 95% confidence interval [CI], 0.84-0.93), especially those on proton-pump-inhibitors or thiazides. Oral magnesium was not related to MACE in 11,838 matched patients with normomagnesemia (HR 1.07; 95% CI, 0.97-1.17).
Conclusions
In patients with T2D, both hypomagnesemia and hypermagnesemia were associated with higher one-year MACE risks compared to normomagnesemia. Prescribed oral magnesium was associated with a reduced MACE risk in hypomagnesemia but not in normomagnesemia.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.